Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D2 Resection and HIPEC in locally advanced gastric carcinoma
2012-005748-12Phase 3Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in gastric adenocarcinoma (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Overall survival. Started Apr 2013; status: active.
02
Drugs
oxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2012-005748-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005748-12.